1. Administered hMSCs reduced insulitis by secreting TSG-6 in NOD mice.
Administered hMSCs reduced insulitis by secreting TSG-6 in NOD mice. A: Experimental scheme. Insulitis was analyzed in the pancreas after weekly two-time infusions of HBSS or hMSCs at various ages. Islet number per pancreatic section (B) and insulitis characterization (C) from HBSS- (n = 3) or hMSC-infused mice (2 × 106, n = 3) at various ages. Values are means ± SD. *P < 0.05; **P < NS, not significant by two-tailed Student t test. Insulitis characterization (D) and insulitis score (E) from 12-week-old mice HBSS (n = 8), Scr siRNA hMSC (2 × 106, n = 6), or TSG-6 siRNA hMSC infused (2 × 106, n = 6) at 10 and 11 weeks of age. Insulitis characterization (F) and insulitis score (G) from 12-week-old mice HBSS (n = 8), hMSC (2 × 106, n = 6), or TSG-6 infused (50 µg, n = 6) at 10 and 11 weeks of age. At least 20 individual islets per mouse were examined for insulitis characterization and score. Insulitis score values are means ± SD. *P < 0.05, **P < 0.005, ***P < by one-way ANOVA. H: Diabetes incidence after diabetogenic splenocytes (107 cells/mouse) pooled from 11-week-old female NOD mice that were intravenously cotransferred with HBSS (n = 8), Scr siRNA–transfected hMSCs (1 × 106, n = 7), or TSG siRNA–transfected hMSCs (1 × 106, n = 7). *P < 0.05 by Kaplan-Meier estimator.
Daniel J. Kota et al. Diabetes 2013;62:
©2013 by American Diabetes Association